A pen notebook and a calculator
Markets

Merck Upgraded to “Outperform” at BMO (MRK)

On Monday analysts at BMO Financial upgraded pharmaceutical company Merck & Co., Inc. ( MRK ) after positive data from two early stage products.

The analysts boosted its rating on Merck from "Market Perform" to "Outperform" with a price target of $50. The target is a +13.5% increase from Friday's closing price o $44.05.

Merck shares were up 47 cents, or +1.07%, in premarket trading on Monday.

The Bottom Line

Shares of Merck ( MRK ) have a 3.81% dividend yield, based on Friday's closing stock price of $44.05. The stock has technical support in the $41-$42 price area. If the shares can firm up, we see overhead resistance around the $46-$48 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK

Other Topics

Stocks

Latest Markets Videos